NAD+ (500 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that sits at the centre of redox chemistry and cellular energy metabolism rather than a receptor-targeting peptide. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed in published subcutaneous protocols, not a recommendation for use in humans or animals.

For a 500 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of 166.7 mg/mL. On a U-100 insulin syringe at that fill, a single unit equals 0.01 mL and delivers roughly 1.67 mg of material, so a 100 mg measurement works out to about 60 units (0.60 mL).

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow ramp used in subcutaneous reference protocols, where the daily amount is stepped up over the first weeks to gauge tolerance before settling at a maintenance level.

Reconstitution Steps

1. Let the sealed lyophilized vial reach room temperature before opening, and wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water with a sterile syringe and inject it slowly down the inside wall of the vial — never directly onto the powder pellet, to limit foaming.
3. Swirl or roll gently until the powder fully dissolves. Do not shake vigorously; aggressive agitation can shear the material.
4. The solution should be clear and colourless. Discard if it appears discoloured or shows any precipitate.
5. Label the vial with the concentration (166.7 mg/mL) and the reconstitution date, then refrigerate at 2–8 °C, protected from light. Inspect for clarity before each draw and use a fresh sterile syringe each time.

Supply-Planning Table

Because NAD+ is dosed daily rather than weekly, vial and syringe counts scale quickly. The table below summarises the totals reported for common run lengths at the maintenance dose.

Supplies Needed

• NAD+ vials (500 mg): ~11 vials for an 8-week run; ~16 for 12 weeks; ~22 for 16 weeks at the 100 mg daily maintenance dose.
• Insulin syringes (U-100, 1 mL): ~56 for 8 weeks, ~84 for 12 weeks, ~112 for 16 weeks — one fresh syringe per daily draw.
• Bacteriostatic water (10 mL bottles): 4 bottles for an 8-week run, 5 for 12 weeks, 7 for 16 weeks.
• Alcohol swabs: 2 × 100-count boxes cover an 8–12 week schedule; 3 boxes for a 16-week run.

Protocol Overview

• Research goal: model replenishment of cellular NAD+ pools and its effect on energy metabolism and mitochondrial function.
• Schedule: once-daily subcutaneous administration in the published reference model.
• Dose band: 50 mg starting, ramping to a 100 mg daily maintenance level.
• Fill: 500 mg lyophilized, reconstituted to 166.7 mg/mL with 3 mL diluent.
• Storage: −20 °C or below dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the 50 mg step for the first week to assess tolerance, then increase by 25 mg to 75 mg in week two.
• Advance to 100 mg daily from week three onward if the prior steps were well tolerated.
• Escalate gradually — moving up too quickly is associated with the disruptive effects noted below.
• Keep administration at a consistent time of day; morning dosing is a common preference for steady exposure modelling.

Storage Instructions

Keep sealed lyophilized vials at −20 °C or below, protected from light, with −80 °C preferred for multi-year storage. Once reconstituted, refrigerate at 2–8 °C and use within about 14 days. Protect the solution from light, avoid freeze-thaw cycles, and inspect for clarity before every draw.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Discard any reconstituted solution that turns discoloured or shows visible particulate.
• Keep the diluent injection slow and aimed at the vial wall to minimise foaming.
• Document each draw — date, volume, remaining material — for reproducibility.

How NAD+ Works

NAD+ is a coenzyme that shuttles electrons in redox reactions across the major energy pathways — glycolysis, the TCA cycle and oxidative phosphorylation — and also serves as a substrate for cellular-maintenance enzymes involved in DNA repair and mitochondrial biogenesis. Tissue NAD+ levels are reported to fall with age and metabolic stress, a decline linked in the literature to reduced mitochondrial output and lower cellular resilience. Replenishing the available pool is the rationale behind the protocols studied here.

Reported Benefits & Side Effects

Benefits described in the literature

• Support for cellular energy production and mitochondrial function via replenishment of NAD+ pools.
• Cognitive-support and metabolic-health signals reported in the 100–300 mg/day range.
• Reduced cravings and improved mood noted in higher-dose intravenous protocols (500–1,500 mg daily).
• No severe adverse events reported across published NAD+/NADH trials.

Side effects reported

• Insomnia, anxiety or fatigue if doses are escalated too quickly.
• Mild injection-site reactions — redness, itching or soreness — with subcutaneous administration.
• Transient headache or flushing, generally dose-dependent.
• Amounts above roughly 200–300 mg/day are typically reserved for supervised therapeutic settings.

Injection Technique (Reference Only)

• A 28–31 gauge insulin syringe with a 5/16–1/2 inch (8–12 mm) needle is sufficient to reach subcutaneous tissue; a 1 mL U-100 syringe suits the 0.30–0.60 mL volumes here.
• Pinch a fold of skin and insert at roughly a 45° angle into the subcutaneous layer; aspiration is not required for subcutaneous work.
• Inject slowly over 5–10 seconds, then pause briefly before withdrawing the needle.
• Clean the site with an alcohol swab and let it air-dry first; rotate between abdominal quadrants (at least 2 inches from the navel), outer thigh and back of the upper arm to avoid soreness or lipohypertrophy, and dispose of sharps in an approved container.

References

Related Protocols